Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions

Catheterization and Cardiovascular Interventions

Volumn 57, Issue 2, 2002, Pages 187-190

  Aslam, Muhammad Shakil ^a   Sundberg, Steve ^a   Sabri, M Nagui ^a   Cooke, David ^a   Lakier, Jeffrey B ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

Coronary angiography; Enoxaparin; Low molecular weight heparin; Percutaneous coronary intervention; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIBODY RESPONSE; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; ENOXAPARIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 0036790778     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10305     Document Type: Article

References (12)

1. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circualtion 1999;100:1593-1601.
2. Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
3. Bozovich GE, Gurfinkel EP, Antman EM, et al. Superiority of Enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J 2000;140:637-642.
4. Antman EM, Cohen M, Bradley D, et al. Assessment of the treatment effect of Enoxaparin for unstable angina/non-Q-wave myocardial infarction, TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
5. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (Enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. J Am Coll Cardiol 2000;36:693-698.
6. Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000;36:1507-1513.
7. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-352.
8. Kereiakes DJ, Fry E, Matthai W, et al. Safety of Enoxaparinabciximab combination for percutaneous coronary intervention: "NICE" guys finish first. J Invas Cardiol 2000;12(Suppl):1A-5A.
9. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous Enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
10. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;4:272-278.
11. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on the laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807.
12. Antman EM, for the TIMI 11A trial investigators. Dose ranging trial of Enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.